Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093119
Status:
COMPLETED
Last Update Posted:
2017-04-26
First Post:
2004-10-01
Brief Title:
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will treat patients previously treated for advanced metastatic melanoma skin cancer with a new chemotherapeutic medicine The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None